Literature DB >> 9539408

Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly.

R W Warzok1, C Kessler, G Apel, A Schwarz, R Egensperger, D Schreiber, E W Herbst, E Wolf, R Walther, L C Walker.   

Abstract

To evaluate the influence of the apolipoprotein E (ApoE) epsilon4 allele on the age at which Alzheimer-like lesions appear in the brain, we analyzed the degree of cerebral beta-amyloidosis and neurofibrillary tangle formation in the hippocampal formation and adjacent cortical areas 28, 27, and 36 of persons who had died between the ages of 50 and 93 years and who had shown no signs of clinical dementia. The occurrence of the three common polymorphisms of the ApoE gene in this sample of 147 routine autopsy cases from eastern Germany was comparable to previously reported values in European and North American populations: ApoEepsilon2/2, 0.7%; ApoEepsilon2/3, 14.3%; ApoEepsilon2/4, 4.1%; ApoEepsilon3/3, 56.5%; ApoEepsilon3/4, 22.4%; and ApoEepsilon4/4, 2.0%. Nondemented persons carrying the ApoEepsilon4 allele were significantly more likely to have senile plaques, diffuse amyloid deposits, cerebrovascular amyloid, and neurofibrillary tangles than were those lacking E4. Comparing the two largest ApoE subgroups, ApoEepsilon3/3 and ApoEepsilon3/4, the relative increase in the occurrence of beta-amyloid in the epsilon3/4 group was evident by the mid-60s, with the relative increase in neurofibrillary tangles in this group emerging slightly earlier. The ApoEepsilon2 allele appears to delay the appearance of the lesions somewhat. We conclude that ApoEepsilon4 promotes the early appearance of beta-amyloid and neurofibrillary tangles in the elderly and that the increased frequency of these lesions is related to the higher risk of Alzheimer disease in persons bearing the ApoEepsilon4 allele.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9539408     DOI: 10.1097/00002093-199803000-00005

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  15 in total

1.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.

Authors:  Y Huang; X Q Liu; T Wyss-Coray; W J Brecht; D A Sanan; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

Review 2.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 4.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

5.  Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.

Authors:  Jean-Cosme Dodart; Robert A Marr; Milla Koistinaho; Beth M Gregersen; Seema Malkani; Inder M Verma; Steven M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-18       Impact factor: 11.205

Review 6.  The Exceptional Vulnerability of Humans to Alzheimer's Disease.

Authors:  Lary C Walker; Mathias Jucker
Journal:  Trends Mol Med       Date:  2017-05-05       Impact factor: 11.951

7.  Influences of APOE ε4 and expertise on performance of older pilots.

Authors:  Joy L Taylor; Quinn Kennedy; Maheen M Adamson; Laura C Lazzeroni; Art Noda; Greer M Murphy; Jerome A Yesavage
Journal:  Psychol Aging       Date:  2011-06

8.  APOE genotypes as a risk factor for age-dependent accumulation of cerebrovascular disease in older adults.

Authors:  Melissa Lamar; Lei Yu; Leah H Rubin; Bryan D James; Lisa L Barnes; Jose Marcelo Farfel; Chris Gaiteri; Aron S Buchman; David A Bennett; Julie A Schneider
Journal:  Alzheimers Dement       Date:  2018-10-12       Impact factor: 21.566

9.  Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.

Authors:  Rebecca F Rosen; Brian J Ciliax; Thomas S Wingo; Marla Gearing; Jeromy Dooyema; James J Lah; Jorge A Ghiso; Harry LeVine; Lary C Walker
Journal:  Acta Neuropathol       Date:  2009-08-19       Impact factor: 17.088

Review 10.  Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?

Authors:  Jens Pahnke; Lary C Walker; Katja Scheffler; Markus Krohn
Journal:  Neurosci Biobehav Rev       Date:  2009-05-27       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.